For example, NKG2D-deficient mice exhibit enhanced tumor control in models of prostate carcinoma, inflammation-driven hepatocellular carcinoma, B16 melanoma, and radiation-induced lymphoma. This evidence concerns the gene KLRK1 and prostate carcinoma.